Centers for Disease Control and Prevention Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z site search
National Office of Public Health Genomics
Centers for Disease Control and Prevention
Office of Genomics and Disease Prevention
Site Search
 

Newborn Screening for Cystic Fibrosis Meeting
Centers for Disease Control and Prevention and Cystic Fibrosis Foundation
November 20th – 21st, 2003
Atlanta, GA

Description | Agenda


Meeting Description

Objectives:

  1. Review and evaluate the scientific evidence on benefits and risks
    of newborn screening for cystic fibrosis

  2. Review the role of screening, diagnostics and follow-up issues in cystic fibrosis newborn screening decision making

  3. Disseminate information about models and ‘best practices” for states that choose to adopt newborn screening for cystic fibrosis

Sponsors:
Centers for Disease Control and Prevention and Cystic Fibrosis Foundation
 

Meeting Agenda
 
November 20 Review of the Evidence
 
 
  Moderator: Coleen Boyle  
 
8:00 a.m.  Welcome and Introductions Coleen Boyle and Preston Campbell
 
8:15 a.m.  Criteria for newborn screening Brad Therrell
     
8:30 a.m.  Overview of evidence-based decision-making for screening interventions Mark Helfand
 
8:45 a.m. Panel discussion on criteria for evidence of benefits Tom Locke, Jeff Botkin, George Cunningham
     
9:15 a.m. Epidemiology and Natural History of CF Preston Campbell and Frank Accurso
     
10:00 a.m. Break
 
 
  Moderator: Preston Campbell  
     
10:15 a.m. Overview of published evidence on outcomes with early detection
  
  Wisconsin clinical trial
 
Phil Farrell 
  Observational data from US Margaret Rosenfeld
     
11:15 a.m. International Experience
 
 
  Published evidence from Europe
 
Jeannette Dankert 
  Recent UK experience
 
Anil Mehta
  New pulmonary outcome data and early therapy for pancreatic deficiency in Australia
 
Karen McKay
  Opportunities for early intervention for Pseudomonas aeruginosa Niels Hoiby
     
 12:15 p.m. Working Lunch (Provided)  
     
  Moderator: Robert Wilmott  
     
1:00 p.m. New data – US  
 

 
  Survival advantage
 
Hui-Chuan Lai
  Cognitive outcomes and quality of life
 
Rebecca Koscik
1:30 p.m. Panel and discussion– Grading the Evidence Mark Helfand, Peter Briss, Muin Khoury, Frank Desposito
 
  Moderator: Ben Wilfond  
     
2:30 p.m. Overview of Risks
 
 
  Potential harms
 
Norman Fost
  False positives and psychosocial risks
 
Jeannette Dankert
  Delayed diagnosis and the family perspective Martin Kharrazi
     
3:15 p.m. Break
     
3:45 p.m. Weighing Risks and Benefits: Screening justification and balancing harm
 
  Discussion panel
 
Richard Parad, Kenneth Fink, Lainie Ross
4:30 p.m. Summary and integration of presented information, discussion of conclusions Coleen Boyle
     
5:30 p.m. Adjourn  
     
November 21 Screening, Diagnosis and Follow-up: The Role They Play in Decision Making
 
  Moderator: Harry Hannon  
     
7:50 a.m. Newborn Screening: The System Brad Therrell
     
8:10 a.m. Planning Challenges for a Successful Screening Program Anne Comeau
     
8:30 a.m. Screening Issues
 
 
  Screening models
 
Ben Wilfond, overview
 
 

Wisconsin
New York
Pediatrix
Colorado

Gary Hoffman
Ken Pass
Dennis Freer
Marci Sontag
 

Topics: IRT, DNA mutations, false positives, false negatives, carriers etc.

  Performance evaluation of laboratories Joanne Mei
     
10:00 a.m. Break
 
 
  Moderator: Michele Puryear  
 
10:15 a.m. Informed Consent
 
 
  How important is informed consent?
 
Ellen Wright Clayton
 
  Implementation of informed consent in a newborn screening program
 
Jean-Louis Dhondt
     
10:45 a.m. Diagnostics and Sweat Testing Referrals
 
  Wisconsin's approach Mike Rock
 
  Massachusetts' approach Richard Parad
     
11:15 a.m. Linking with CF Centers for care of diagnosed infants
 
  Massachusetts Experience Hank Dorkin
 
  New York experience Robert Kaslovsky
     
11:45 a.m. Lunch (Provided)  
  Moderator: George Cunningham  
     
12:30 p.m. Rapporteur
 
George Cunningham (CA)
 
  Panel – Implications for state programs considering screening for CF Pam King (OK), Jerry McClure (MS), Kathy Tomashitis (SC)
     
1:30 p.m. Communication with parents and providers, including challenge of genetic counseling – issues and protocols
 
  Communication perspective James Dillard
 
  Massachusetts experience Anne Comeau
     
2:00 p.m. Costs of screening  
  Wisconsin experience Phil Farrell
 
  Discussion Scott Grosse
     
2:30 p.m. Break  
     
3:00 p.m. Tying it Together: Weighing the Evidence for a Public Health Response to Cystic Fibrosis – Jeff Botkin
     
3:45 p.m. Closing remarks Coleen Boyle & Preston Campbell
     
4:00 p.m. Adjourn  
     

Page last reviewed: June 8, 2007 (archived document)
Page last updated: November 2, 2007
Content Source: National Office of Public Health Genomics